Erik J Landaas1, Gary Franklin2, Jeff Thompson3, Dan Lessler4, Josiah Morse4, Robert Mootz5, Steven G Hammond6, Sean D Sullivan7. 1. University of Washington School of Pharmacyerikl@uw.edu. 2. Washington State Department of Labor & Industries,Office of the Medical DirectorUniversity of Washington School of Public Health. 3. Willis Towers Watson. 4. Washington State Health Care Authority. 5. Washington State Department of Labor & Industries,Office of the Medical Director. 6. Washington State Department of Corrections. 7. University of Washington School of Pharmacy.
Abstract
OBJECTIVES: We describe a new evidence-based method for screening and evaluating emerging medical technologies. Washington State agencies, under legislative direction, have granted authority to its agency Medical Directors and policy leaders to make coverage decisions on medical technologies using a "dossier" process. The dossier process is employed when technology advocates or manufacturers request Washington State healthcare purchasers to pay for new and emerging technologies. This offers the advocate an opportunity to submit scientific evidence and information classically associated with a more formal health technology assessment. METHODS: The submitted information is independently reviewed and summarized for Washington State's public healthcare purchasers allowing a more standardized coverage decision for all public purchasers in Washington State. RESULTS: This process has allowed Washington State to make twelve evidence-based coverage decisions at a fraction of the cost of classic technology assessment. To date, of twelve reviews over 6 years, one health technology was approved for coverage, ten were not covered and one did not require a coverage decision. CONCLUSIONS: This evidence-based dossier process has yielded high-value coverage decisions of new and emerging medical technologies for public healthcare purchasers in Washington State.
OBJECTIVES: We describe a new evidence-based method for screening and evaluating emerging medical technologies. Washington State agencies, under legislative direction, have granted authority to its agency Medical Directors and policy leaders to make coverage decisions on medical technologies using a "dossier" process. The dossier process is employed when technology advocates or manufacturers request Washington State healthcare purchasers to pay for new and emerging technologies. This offers the advocate an opportunity to submit scientific evidence and information classically associated with a more formal health technology assessment. METHODS: The submitted information is independently reviewed and summarized for Washington State's public healthcare purchasers allowing a more standardized coverage decision for all public purchasers in Washington State. RESULTS: This process has allowed Washington State to make twelve evidence-based coverage decisions at a fraction of the cost of classic technology assessment. To date, of twelve reviews over 6 years, one health technology was approved for coverage, ten were not covered and one did not require a coverage decision. CONCLUSIONS: This evidence-based dossier process has yielded high-value coverage decisions of new and emerging medical technologies for public healthcare purchasers in Washington State.
Keywords:
Coverage decisions; Devices; Evidence-based medicine; Health technologies; Technology assessment